IP Library Granted Patent US 10,980,802
Granted Patent B2
US 10,980,802 · App. 16/043,219 · Granted Apr 20, 2021

Medicament for treating mental and behavioural disorders

Inventor: Tsuyoshi Tsujimura (Osaka, JP)
Assignee: Sumitomo Dainippon Pharma Co., Ltd.
A61K31/496
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,980,802
App. No.
16/043,219
Granted
Apr 20, 2021
Kind
B2
Abstract

The present invention relates to a medicament comprising lurasidone or a pharmaceutically acceptable acid addition salt thereof for treating pervasive developmental disorders and a method of the treatment thereof.

Claims (8)

1. A method for treating impairment in social adaptive function or impairment in communication in a mental and behavioral disorder selected from the group consisting of pervasive developmental disorder, a genetic disease accompanied by autism-like symptoms, and a congenital disease accompanied by autism-like symptoms, comprising:

administering a therapeutically effective amount of lurasidone or a pharmaceutically acceptable acid addition salt thereof as a sole active ingredient to a mammal with said mental and behavioral disorder.

2. The method of claim 1 wherein the mental and behavioral disorder is a pervasive developmental disorder.

3. The method of claim 2 wherein the pervasive developmental disorder is selected from the group consisting of atypical autism, Rett's syndrome, childhood disintegrative disorder, overactive disorder associated with mental retardation and stereotyped movements, and Asperger's syndrome.

4. The method of claim 1 wherein the mental and behavioral disorder is a genetic disease accompanied by autism-like symptoms.

5. The method of claim 4 wherein the genetic disease is fragile X syndrome or phenylketonuria.

6. The method of claim 1 wherein the mental and behavioral disorder is a congenital disease accompanied by autism-like symptoms.

7. The method of claim 6 wherein the congenital disease is congenital rubella syndrome or cytomegalic inclusion body disease.

Assignments (1)
CHANGE OF NAME Recorded Nov 21, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 061972/0730 →
Priority Claims (1)
JP 2012-100816 · Apr 26, 2012 · national
Continuity (3)
Continuation 13827655 · Mar 14, 2013
Provisional Application 61638725 · Apr 26, 2012
Related Publication 20180344730A1 · Dec 6, 2018